Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
DongSheng Wen
Observed names:
Dongsheng Wen,
Wen, DongSheng,
Wen, Dongsheng
Institutions:
Sun Yat-sen University Cancer Center,
State Key Laboratory of Oncology in South China
Observed institutions:
Sun Yat-sen University,
Sun Yat-sen University Cancer Center,
State Key Laboratory of Oncology in South China
ORCID:
0000-0002-6842-8551
Observed ORCID:
0000-0002-6842-8551
OpenAlex ID:
A5013909909
Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)
2023
·
MinKe He
, YeXing Huang
, et al.
·
Clinical Cancer Research
·
23
Clinical and biomarker analyses of hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitor for patients with advanced intrahepatic cholangiocarcinoma
2024
·
YeXing Huang
, ZeFeng Du
, et al.
·
Frontiers in Immunology
·
19
PDF
Hepatic Arterial Infusion Chemotherapy plus either Toripalimab or Sorafenib as First‐line Therapy for Locally Advanced Hepatocellular Carcinoma: A Non‐comparative, Randomized Phase 2 Trial
2026
·
Zhicheng Lai
, Aojie Ge
, et al.
·
MedComm
Genome-Scale CRISPR Screens Reveal DNA Repair Dependencies That Sensitize Hepatocellular Carcinoma to Oxaliplatin
2026
·
Hanyue Ouyang
, Diyun Huang
, et al.
·
Cancers
PDF
Table S5 from Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)
2023
·
MinKe He
, YeXing Huang
, et al.
Figure S9 from Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)
2023
·
MinKe He
, YeXing Huang
, et al.
Figure S10 from Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)
2023
·
MinKe He
, YeXing Huang
, et al.
Table S5 from Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)
2023
·
MinKe He
, YeXing Huang
, et al.
Table S1 from Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)
2023
·
MinKe He
, YeXing Huang
, et al.
Figure S6 from Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)
2023
·
MinKe He
, YeXing Huang
, et al.
Table S3 from Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)
2023
·
MinKe He
, YeXing Huang
, et al.
Table S4 from Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)
2023
·
MinKe He
, YeXing Huang
, et al.
Table S6 from Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)
2023
·
MinKe He
, YeXing Huang
, et al.
Supplement 1 from Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)
2023
·
MinKe He
, YeXing Huang
, et al.
PDF
Figure S5 from Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)
2023
·
MinKe He
, YeXing Huang
, et al.
PDF
Figure S1 from Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)
2023
·
MinKe He
, YeXing Huang
, et al.
PDF
Table S2 from Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)
2023
·
MinKe He
, YeXing Huang
, et al.
PDF
Figure S3 from Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)
2023
·
MinKe He
, YeXing Huang
, et al.
Figure S13 from Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)
2023
·
MinKe He
, YeXing Huang
, et al.
PDF
Figure S11 from Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)
2023
·
MinKe He
, YeXing Huang
, et al.
Figure S12 from Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)
2023
·
MinKe He
, YeXing Huang
, et al.
PDF
Figure S3 from Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)
2023
·
MinKe He
, YeXing Huang
, et al.
PDF
Table S2 from Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)
2023
·
MinKe He
, YeXing Huang
, et al.
Figure S4 from Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)
2023
·
MinKe He
, YeXing Huang
, et al.
PDF
Supplement 2 from Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)
2023
·
MinKe He
, YeXing Huang
, et al.
Show more works
View as search
Works count:
43
Citation count:
42
H-index:
2
I10-index:
2
Year
Topic
Type